{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:45:51Z","timestamp":1754153151359,"version":"3.41.2"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>There are limited long-term outcome data comparing BioLinx polymer (B)-zotarolimus-eluting stents (ZES) with phosphorylcholine polymer (P)-ZES. The aim of this study was to compare the efficacy and safety of B-ZES with P-ZES in patients who underwent percutaneous coronary intervention (PCI) during a 3-year follow-up period.<\/jats:p>\n            <jats:p>One thousand two hundred fifty four patients who underwent PCI with P-ZES (Endeavor [ZES-E] or Endeavor sprint [ZES-S], n\u200a=\u200a356) or B-ZES (Endeavor resolute [ZES-R] or Resolute Integrity [ZES-I], n\u200a=\u200a889) were enrolled. The primary endpoint was major adverse cardiac events (MACE); the composite of total death, non-fatal myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), non-target vessel revascularization (Non-TVR), and the secondary endpoint was stent thrombosis (ST).<\/jats:p>\n            <jats:p>After PSM, 2 propensity-matched (PSM) groups (275 pairs, n\u200a=\u200a550, C-statistic\u200a=\u200a0.730) were generated. During the 3-year follow-up period, the cumulative incidence of MACE (hazard ratio [HR], 1.525; 95% confidence interval [CI], 0.920\u20132.526; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.101) and ST (HR, 1.248; 95% CI, 0.335\u20134.4649; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.741) were similar between P-ZES and B-ZES after PSM. However, TLR rate was significantly higher in ZES-S than ZES-I (11.3% vs 3.8%, log rank <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.029) and TVR rate was higher in ZES-S than ZES-R (14.1% vs 4.8%, log rank <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.025).<\/jats:p>\n            <jats:p>In this single-center, all-comer registry, despite different polymers, P-ZES, and B-ZES showed comparable safety and efficacy during a 3-year follow-up period after PCI.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000016767","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:40:51Z","timestamp":1565224851000},"page":"e16767","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Three-year major clinical outcomes of phosphorylcholine polymer- vs biolinx polymer-zotarolimus-eluting stents"],"prefix":"10.1097","volume":"98","author":[{"given":"Yong Hoon","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ae-Young","family":"Her","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Woon","family":"Rha","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung Geol","family":"Choi","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Yeon","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Korea University Graduate School, Seoul"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Kyeong","family":"Byun","sequence":"additional","affiliation":[{"name":"Department of Medicine, Korea University Graduate School, Seoul"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoonjee","family":"Park","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Oh","family":"Kang","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Young","family":"Jang","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woohyeun","family":"Kim","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woong Gil","family":"Choi","sequence":"additional","affiliation":[{"name":"Cardiology Department, Konkuk University Chungju Hospital, Chungju"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Soo","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cardiovascular Division, Dankook University Hospital, Cheonan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihun","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Soonchunhyang University Gumi Hospital, Gumi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Ho","family":"Park","sequence":"additional","affiliation":[{"name":"Cardiology Department, Soonchunhyang University Cheonan Hospital, Cheonan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Young","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Nowon Eulji Medical Center, Eulji University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Ho","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Soonchunhyang University College of Medicine, Seoul, South Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheol Ung","family":"Choi","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Gyu","family":"Park","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Seog","family":"Seo","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Korea University Guro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250722","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1056\/NEJMoa067484","article-title":"Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents","volume":"356","author":"Kastrati","year":"2007","journal-title":"N Engl J Med"},{"key":"R2-20250722","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/CIRCULATIONAHA.106.666800","article-title":"Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern","volume":"115","author":"Camenzind","year":"2007","journal-title":"Circulation"},{"key":"R3-20250722","first-page":"157","article-title":"First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial","volume":"1","author":"Meredith","year":"2005","journal-title":"EuroIntervention"},{"key":"R4-20250722","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1161\/01.CIR.104.8.852","article-title":"Bench to bedside: the development of rapamycin and its application to stent restenosis","volume":"104","author":"Marx","year":"2001","journal-title":"Circulation"},{"key":"R5-20250722","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ahj.2013.07.033","article-title":"Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-Eluting Endeavor Sprint stent in uncertain DES candidates study","volume":"166","author":"Valgimigli","year":"2013","journal-title":"Am Heart J"},{"key":"R6-20250722","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/jbm.a.31664","article-title":"Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent","volume":"85","author":"Udipi","year":"2008","journal-title":"J Biomed Mater Res A"},{"key":"R7-20250722","first-page":"137","article-title":"The next generation Endeavor Resolute Stent: role of the BioLinx polymer system","volume":"3","author":"Udipi","year":"2007","journal-title":"EuroIntervention"},{"key":"R8-20250722","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jacc.2011.03.005","article-title":"Clinical evaluation of the resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial","volume":"57","author":"Yeung","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R9-20250722","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.105.591206","article-title":"Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial","volume":"114","author":"Fajadet","year":"2006","journal-title":"Circulation"},{"key":"R10-20250722","doi-asserted-by":"crossref","first-page":"45m","DOI":"10.1016\/j.amjcard.2007.08.021","article-title":"Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients","volume":"100","author":"Gershlick","year":"2007","journal-title":"Am J Cardiol"},{"key":"R11-20250722","doi-asserted-by":"crossref","first-page":"E296","DOI":"10.25011\/cim.v38i5.25686","article-title":"Does stent strut design impact clinical outcomes: comparative safety and efficacy of Endeavor Resolute versus Resolute Integrity zotarolimus-eluting stents","volume":"38","author":"Di Santo","year":"2015","journal-title":"Clin Invest Med"},{"key":"R12-20250722","doi-asserted-by":"crossref","first-page":"942","DOI":"10.4244\/EIJV10I8A161","article-title":"Impact of technological developments in drug-eluting stents on patient-focused outcomes: a pooled direct and indirect comparison of randomised trials comparing first- and second-generation drug-eluting stents","volume":"10","author":"Colmenarez","year":"2014","journal-title":"EuroIntervention"},{"key":"R13-20250722","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijcard.2016.12.116","article-title":"Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: a meta-analysis of randomized trials","volume":"230","author":"Bavishi","year":"2017","journal-title":"Int J Cardiol"},{"key":"R14-20250722","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/euhj.2000.2305","article-title":"Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology\/American College of Cardiology Committee for the redefinition of myocardial infarction","volume":"21","year":"2000","journal-title":"Eur Heart J"},{"key":"R15-20250722","doi-asserted-by":"crossref","first-page":"e2651","DOI":"10.1097\/MD.0000000000002651","article-title":"Is there any significant difference in stent thrombosis between sirolimus and paclitaxel eluting stents?: a systematic review and meta-analysis of randomized controlled trials","volume":"95","author":"Bundhun","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R16-20250722","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/MCA.0b013e328333f550","article-title":"Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent","volume":"21","author":"Doostzadeh","year":"2010","journal-title":"Coron Artery Dis"},{"key":"R17-20250722","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1210816","article-title":"Drug-eluting coronary-artery stents","volume":"368","author":"Stefanini","year":"2013","journal-title":"N Engl J Med"},{"key":"R18-20250722","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jcin.2009.07.007","article-title":"Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial","volume":"2","author":"Meredith","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"R19-20250722","doi-asserted-by":"crossref","first-page":"562","DOI":"10.4244\/EIJV6I5A95","article-title":"Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study","volume":"6","author":"Fajadet","year":"2010","journal-title":"EuroIntervention"},{"key":"R20-20250722","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jcin.2009.10.009","article-title":"Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)","volume":"2","author":"Eisenstein","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"R21-20250722","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jcin.2012.04.008","article-title":"3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents","volume":"5","author":"Maeng","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"R22-20250722","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.4244\/EIJ-D-16-00571","article-title":"Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial","volume":"12","author":"van der Heijden","year":"2017","journal-title":"EuroIntervention"},{"key":"R23-20250722","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.002223","article-title":"Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis","volume":"8","author":"Piccolo","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"R24-20250722","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2012.10.019","article-title":"Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease","volume":"165","author":"Tada","year":"2013","journal-title":"Am Heart J"},{"key":"R25-20250722","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1253\/circj.CJ-15-1119","article-title":"Angioscopic comparison of resolute and endeavor zotarolimus-eluting stents","volume":"80","author":"Nishimoto","year":"2016","journal-title":"Circ J"},{"key":"R26-20250722","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4068\/cmj.2018.54.1.55","article-title":"Safety and efficacy of the Endeavor Resolute\u00ae Stent in patients with multivessel disease: the HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial","volume":"54","author":"Sim","year":"2018","journal-title":"Chonnam Med J"},{"key":"R27-20250722","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcin.2012.12.123","article-title":"The \u201cfinal\u201d 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent","volume":"6","author":"Kirtane","year":"2013","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201908090-00056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T16:01:01Z","timestamp":1753200061000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201908090-00056"}},"subtitle":["A propensity score matching study"],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":27,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000016767","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"2019-01-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}